Carvedilol Tablet 25mg (Carvedilol)

Adult dose

Do not increase the dose or discontinue treatment without a physician's instructions. Essential hypertension, adults: For the first 2 days, administer carvedilol 12.5 mg orally once daily, then 25 mg orally once daily. Usually, administer 25 mg orally once daily for 2 weeks. If dose escalation is required, increase to 25 mg twice daily. The maximum dose per administration is 25 mg, and the maximum daily dose is 50 mg. Essential hypertension, elderly patients: In some elderly patients, 12.5 mg once daily may be sufficient. However, the dose may be increased if the effect is insufficient after 2 weeks of treatment. Chronic stable angina: For the first 2 days, administer this drug 12.5 mg orally twice daily, then 25 mg orally twice daily. Usually, administer 25 mg twice daily for 2 weeks. If dose escalation is required (excluding elderly patients), the dose may be increased up to 50 mg twice daily.

This medication should not be used in certain patients. For example, patients with allergies to this medication or its components, patients with cardiogenic shock, patients with severe heart conduction disorders, patients with cor pulmonale, patients with diabetic ketoacidosis, patients with severely compromised heart function, patients with asthma or chronic obstructive pulmonary disease, patients with secondary hypertension, patients with Prinzmetal angina, patients with acute pulmonary embolism, pheochromocytoma patients, certain antidepressant users, patients with severe hypotension, patients with severe liver dysfunction, pregnant or breastfeeding women, patients with peripheral circulatory disorders, patients with laryngeal edema, patients with complications of myocardial infarction, patients with severe fluid retention, patients with allergic rhinitis, and patients with lactose intolerance should not use this medication. Additionally, careful administration is required for diabetic patients or patients with a history of hypersensitivity, patients with a history or family history of skin disorders caused by beta-blockers, patients with ischemic heart disease complicated by hypotension, patients with unstable angina, patients with chronic congestive heart failure, patients with severe renal impairment, patients with first-degree atrioventricular block, patients with bradycardia, patients currently using eyedrop forms of beta-blockers, elderly patients, patients with blood pressure dropping upon position change, patients with acute inflammatory heart disease, patients taking certain antihypertensive medications, patients with salt or water depletion, patients taking cardiac glycosides, patients using calcium channel blockers or antiarrhythmics, fasting patients, patients with hyperthyroidism, contact lens users, patients under 18 years of age, and hemodynamically unstable patients with acute myocardial infarction, as well as patients with hypertension and coronary artery disease. This medication may cause dizziness, headache, fatigue, and, in severe cases, hallucinations or psychotic symptoms. Cardiac-related adverse reactions may include bradycardia, shock, heart failure, and cardiac arrest; therefore, regular monitoring of heart function is necessary. Furthermore, dizziness or loss of consciousness due to blood pressure drop may occur, so caution is advised. In patients with renal impairment, deterioration of kidney function may occur, and in patients with respiratory diseases, respiratory resistance may increase. Gastrointestinal symptoms may include nausea, diarrhea, abdominal pain, and vomiting, while skin reactions may include hives, itching, and rashes. Rarely, changes in liver function markers or thrombocytopenia and leukopenia have been reported as blood abnormalities. This medication may complicate blood sugar control in diabetic patients and may mask symptoms of hyperthyroidism. Cardiovascular adverse reactions such as bradycardia, hypotension, and worsening angina may also occur. Long-term use requires regular monitoring of heart function, blood pressure, electrocardiogram, liver and kidney function, and blood tests, as sudden discontinuation may worsen cardiac symptoms. Gradual tapering according to a physician's guidance is essential. Caution is also necessary when driving or performing hazardous tasks, as drowsiness or dizziness may occur. This medication has many drug interactions, so if you are taking other medications, it is essential to inform your physician or pharmacist, particularly when taking antihypertensives, antidepressants, sedatives, anesthetics, hypoglycemics, calcium channel blockers, antiarrhythmics, cyclosporine, and alcohol. Pregnant or potentially pregnant women and breastfeeding women should not take this medication, and safety for children and adolescents has not been established. Elderly patients may experience increased drug concentrations due to liver function reduction, and they should start with a lower dose due to the risk of cerebral infarction from blood pressure reduction. In case of overdose, symptoms may include hypotension, decreased heart rate, myocardial weakness, shock, difficulty breathing, and consciousness disorders, requiring immediate medical attention and appropriate treatment. This medication is sensitive to light, so it should be stored in a light-resistant container and kept out of reach of children. Transferring to other containers may compromise quality, so caution is advised.

• Dizziness
• headache
• fatigue
• weakness
• hallucinations
• confusion
• depression
• sleep disorders
• nightmares
• psychosis

This medication is sensitive to light and should be stored in a container that does not allow light. Additionally, to maintain its efficacy, it is important to store at room temperature, specifically between 1°C and 30°C.

Appearance

White round tablet

Package unit

90 tablets/PTP [(10 tablets/PTP*9)]